Record overview
Status and phase
Status: TERMINATED
Phase: PHASE2
Sponsor: Prisma Health-Upstate
Condition: Cancer, Rare Disease
NCT02938793
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Registry Stop Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
poor enrollment likely due to expanded availability of immunotherapy for patients